» Articles » PMID: 22125781

Persistent Asthma Has an Accumulative Impact on the Loss of Smell in Patients with Nasal Polyposis

Overview
Journal Rhinology
Date 2011 Nov 30
PMID 22125781
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Loss of sense of smell is one of the most frequent complaints in patients with nasal polyposis (NP). The aim of this study was to evaluate the impact of asthma and its severity on the sense of smell.

Material And Methods: Patients with massive NP and healthy controls were included. More than half of patients presented with asthma. Olfactometry by Barcelona Smell Test 24, nasal symptoms score, nasal endoscopy, allergy study, and paranasal sinus CT scan were assessed.

Results: NP patients showed a significant impairment in smell detection, identification, and forced choice compared to the control. Asthmatics reported lower scores for detection, identification, and forced choice than non-asthmatic patients. Patients with persistent asthma had an increased impairment of sense of smell on detection, identification, and forced choice than patients with intermittent asthma. No significant differences were found between mild, moderate, and severe persistent asthmatics. Paranasal sinuses opacification was inversely correlated with smell detection, identification and forced choice.

Conclusion: These findings suggest that patients with NP have an impaired sense of smell, that asthma -particularly persistent asthma- has a further impact on sense of smell, and that loss of smell may be used as a clinical tool to identify the severity of both NP and asthma.

Citing Articles

A RESPONSE to antiIL-5 therapy in comorbid patients with chronic rhinosinusitis with nasal polyps and severe asthma: Study protocol.

Bakakos P, Alobid I, Constantinidis J, Hellings P, Pfaar O, Taille C J Allergy Clin Immunol Glob. 2024; 4(1):100343.

PMID: 39554605 PMC: 11567123. DOI: 10.1016/j.jacig.2024.100343.


Using Zebrafish to Study Multiciliated Cell Development and Disease States.

Nguyen T, Baker S, Rodriguez J, Arceri L, Wingert R Cells. 2024; 13(21.

PMID: 39513856 PMC: 11545745. DOI: 10.3390/cells13211749.


Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada.

Yong M, Kirubalingam K, Desrosiers M, Kilty S, Thamboo A Allergy Asthma Clin Immunol. 2023; 19(1):90.

PMID: 37838713 PMC: 10576384. DOI: 10.1186/s13223-023-00823-1.


Chronic rhinosinusitis with nasal polyps and allergic rhinitis as different multimorbid treatable traits in asthma.

Castillo J, Plaza V, Rodrigo G, Julia B, Picado C, Fernandez C J Allergy Clin Immunol Glob. 2023; 2(4):100134.

PMID: 37781668 PMC: 10510007. DOI: 10.1016/j.jacig.2023.100134.


Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.

Fokkens W, Trigg A, Lee S, Chan R, Diamant Z, Hopkins C J Patient Rep Outcomes. 2023; 7(1):4.

PMID: 36662344 PMC: 9859976. DOI: 10.1186/s41687-023-00543-5.